In the typically-slow month of August, nine IPOs raised $1.0 billion, joined by 31 SPACs. Only four of the nine offerings raised over $100 million. Activity was well below August 2020, which saw investors and bankers skip their vacations due to the pandemic....read more
The summer IPO market is wrapping up, and while we could see a few more launches, this past week’s two deals should be some of the last IPOs before fall. SPAC activity continued to bounce back, with 17 blank check IPOs during the week. After slashing...read more
Eliem Therapeutics, a Phase 2a biotech developing therapies for neuronal excitability disorders, raised $80 million by offering 6.4 million shares at $12.50, as expected. The company offered 0.4 million more shares than anticipated. It originally planned to...read more
Eliem Therapeutics, a Phase 2a biotech developing therapies for neuronal excitability disorders, lowered the proposed deal size for its upcoming IPO on Monday. The Redmond, WA-based company now plans to raise $75 million by offering 6 million shares at $12.50....read more
Renaissance Capital’s August IPO Market Update
In the typically-slow month of August, nine IPOs raised $1.0 billion, joined by 31 SPACs. Only four of the nine offerings raised over $100 million. Activity was well below August 2020, which saw investors and bankers skip their vacations due to the pandemic....read more
US IPO Weekly Recap: Summer’s last wave with 2 IPOs
The summer IPO market is wrapping up, and while we could see a few more launches, this past week’s two deals should be some of the last IPOs before fall. SPAC activity continued to bounce back, with 17 blank check IPOs during the week. After slashing...read more
Nervous system biotech Eliem Therapeutics prices IPO at $12.50
Eliem Therapeutics, a Phase 2a biotech developing therapies for neuronal excitability disorders, raised $80 million by offering 6.4 million shares at $12.50, as expected. The company offered 0.4 million more shares than anticipated. It originally planned to...read more
Nervous system biotech Eliem Therapeutics lowers deal size by 7% ahead of $75 million IPO
Eliem Therapeutics, a Phase 2a biotech developing therapies for neuronal excitability disorders, lowered the proposed deal size for its upcoming IPO on Monday. The Redmond, WA-based company now plans to raise $75 million by offering 6 million shares at $12.50....read more